focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 1.00 (5.714%)
Open: 18.00
High: 18.00
Low: 18.00
Prev. Close: 18.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GoFigure® distribution agreement for Poland

22 May 2019 07:00

RNS Number : 7617Z
OptiBiotix Health PLC
22 May 2019
 

OptiBiotix Health plc

("OptiBiotix")

 

GoFigure® distribution agreement for Poland

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol and diabetes, announces it has appointed Extensor as its exclusive distributor of OptiBiotix's own label GoFigure® consumer weight management products in Poland.

 

The agreement grants Extensor the exclusive rights to import, market and distribute OptiBiotix's GoFigure® range of meal replacements, flapjacks and mueslis containing its award winning SlimBiome® technology within the Polish market. This agreement has been signed accompanied by an initial modest five figure order and registration of gofigure.pl for online promotion of the products within the Polish market.

 

Extensor is a well-known Polish brand that was established over 19 years ago for the creation and promotion of products with the highest quality and safety levels in the Health and Wellness sector. The company works with world leaders in the whey protein industry and in 2002, introduced high-protein supplements to the Polish market. Extensor has an extensive distribution network across Poland and is sold through multiple on-line channels, wholesalers, and retail outlets across shops in Poland.

 

This agreement is a strategic step to take OptiBiotix's own label GoFigure® products to international markets. This builds GoFigure® brand recognition, enhancing brand value, and creates a further demand for SlimBiome®, the functional ingredient within Gofigure® products.

 

Christina Wood, Sales & Marketing Director commented: "We are pleased to announce this exclusive distribution deal for the commercialisation of our GoFigure® products in the Polish market. This is part of a commercial strategy of working across multiple levels of the value chain (manufacturer, formulator and distributor) for the supply of white label and own label branded products. This is the first step in taking OptiBiotix's own label GoFigure® products to international markets. This increases brand recognition and value in addition to creating a demand for SlimBiome®, the functional ingredient within GoFigure® products. This means we are able to derive revenue from both the sale of our own brand GoFigure® products and SlimBiome®."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner

 

finnCap (Broker)

 

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)

Camille Gochez (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

 

 

 

About OptiBiotix - www.optibiotix.com 

 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUAANRKKAVUAR
Date   Source Headline
9th Jun 20157:00 amRNSStrategic Development and Commercial Alliance
5th Jun 20152:32 pmRNSExercise of Warrants and Issue of Equity
3rd Jun 20155:50 pmRNSHolding(s) in Company
2nd Jun 20157:00 amRNSContract with multinational consumer goods company
29th May 20157:00 amRNSFinal Results
28th May 20157:00 amRNSNew patent filings
26th May 20157:01 amRNSExercise of Warrants and Issue of Equity
15th May 20153:22 pmRNSHolding(s) in Company
13th May 20157:00 amRNSNotice of Results
21st Apr 20152:24 pmRNSExercise of Warrants and Issue of Equity
17th Apr 20157:00 amRNSResearch Update
14th Apr 20157:00 amRNSUK Investor Show attendance
10th Apr 20154:35 pmRNSPrice Monitoring Extension
8th Apr 20155:26 pmRNSHolding(s) in Company
31st Mar 20155:32 pmRNSGrant of Options
25th Mar 201512:54 pmRNSHolding(s) in Company
20th Mar 201510:32 amRNSExercise of Warrants and Issue of Equity
10th Mar 20157:02 amRNSContract signed with NIZO Food Research
23rd Feb 20157:00 amRNSInvestor Teach In
18th Feb 20157:00 amRNSBoard Appointment
4th Feb 20154:03 pmRNSHolding(s) in Company
21st Jan 20157:00 amRNSJoint venture with Nizo Food Research
20th Jan 20153:23 pmRNSExercise of Warrants and Issue of Equity
15th Jan 20157:00 amRNSAdditions to Scientific Advisory Group
9th Jan 20152:24 pmRNSExercise of Warrants and Issue of Equity
15th Dec 20147:00 amRNSCompletion of ethics approval & study recruitment
10th Dec 20147:00 amRNSChange of Adviser
2nd Dec 20147:00 amRNSSuccessful completion of pre-clinical studies
28th Nov 20142:34 pmRNSHolding(s) in Company
28th Nov 20147:00 amRNSProduct showcased at Health Ingredients Europe
27th Nov 20144:57 pmRNSExercise of Warrants
25th Nov 20147:00 amRNSAppointment of Non-Executive Director
18th Nov 20147:00 amRNSAppointment of Head of Research
14th Nov 20142:46 pmRNSIssue of Equity
11th Nov 20147:00 amRNSContract Signed to Start Clinical Studies
28th Oct 20147:00 amRNSIncorporation of Weight Management Formulation
20th Oct 20147:00 amRNSScientific Advisory Group
1st Oct 20144:08 pmRNSExercise of Warrants
17th Sep 20147:00 amRNSContract signed with Nizo Food Research
5th Aug 20147:00 amRNSFirst day of dealings on AIM
4th Aug 20143:27 pmRNSChange of Name
4th Aug 201411:19 amRNSResult of General Meeting
18th Jul 20144:08 pmRNSExercise of Warrants and Issue of Equity
18th Jul 20147:30 amRNSSchedule 1 - Ducat Ventures plc
18th Jul 20147:30 amRNSRestoration - Ducat Ventures plc
18th Jul 20147:00 amRNSPublication of Admission Document & Restoration...
18th Jul 20147:00 amRNSHalf Yearly Results
9th May 201411:05 amRNSTemporary Suspension
9th May 201411:03 amRNSSuspension - Ducat Ventures Plc
24th Feb 20142:54 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.